Cellectar Biosciences, Inc. (CLRB) Form 10-Q — Aug 13, 2026
Cellectar Biosciences' 10-Q for the quarter ended June 30, 2026 discloses substantial doubt about its ability to continue as a going concern, stating the company may be unable to fund operations under normal course beyond the second quarter of 2027 absent additional capital. Accumulated deficit reached approximately $281.7 million. Cash stood at $34.0 million after a May 2026 financing that grossed roughly $35 million ($31.7 million net), with up to $105 million more available through milestone-based warrants tied to Phase 3 initiation, FDA NDA acceptance, and NDA approval.
Key figures
- Cash Position
- 33993982
- Gross Proceeds
- 35000000
- Shares Outstanding
- 9452108
- Q2 2026 net loss
- 6930653
- Q2 2026 ga expense
- 2639000
- Q2 2026 rd expense
- 4557000
- Accumulated deficit
- 281718099
- Six month rd expense
- 7565000
- Cash runway statement
- Absent further action, may be unable to fund operations under normal course beyond the second quarter of 2027
- Warrant shares issuable
- 52654122
- Q2 2026 rd yoy change pct
- 91
- Total stockholders equity
- 29871833
- Potential milestone financing
- 105000000
- May 2026 offering net proceeds
- 31700000
- Cash used in operations six months
- 10855742
- Unrestricted liquidity at issuance
- 29000000
Price after filing
Close on the filing date to close N calendar days later (from $2.64). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.